Dec. 27 at 9:46 PM
$LGVN I’ve seen this movie before.
I owned Chimerix (CMRX) when it was just a hidden-away pediatric cancer story. Same comments from back then: too niche, too small, bad MGMT, market didn’t care.
Then the FDA clearly got interested - and overnight the narrative changed. Same underlying science. Same patient's outcome.
Pediatric programs like LGVN's only get priced when regulatory alignment removes doubt. Until then, the opportunity is invisible to the market and big pharma - even when the economics are real, and the need is unmet.
There’s also a big misconception around MSCs, coming from decades of unregulated “stem cell clinic” noise — even when the biology, manufacturing, and clinical rigor are entirely different.
With CMRX, the re-rating happened overnight once FDA validation flipped the risk perception.
So, not "bad MGMT" - something different - not advice - just sharing some pattern recognition from personal experience - continue to buy and looking forward to a pivotal year.
